Tamoxifen and Combination Chemotherapy as Adjuvant Treatment in Postmenopausal Women with Breast Cancer

  • A. Wallgren
  • E. Baral
  • U. Beling
  • J. Carstensen
  • S. Friberg
  • U. Glas
  • M. Kaigas
  • L. Skoog
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 96)

Abstract

The general acceptance of breast cancer as a systemic disorder with lymph node metastases as an indicator of poor prognosis has stimulated the search for effective means to control micrometastases. While the early trials on prolonged adjuvant chemotherapy significantly delayed the onset of relapse in premenopausal women, breast cancer in the postmeno­pausal group of patients was apparently less affected [1, 2]. In postmenopausal women tamoxifen has proved to be of value in the palliative treatment of advanced breast cancer and has usually few and mild side effects. Several groups of investigators have therefore included tamoxifen in the adjuvant treatment of breast cancer, either alone or in combination with cytotoxic chemotherapy; for a review consult Mouridsen and Palshof [3].

Keywords

Toxicity Depression Estrogen Oncol Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher B, Carbone P, Economou SG, et al. (1975) L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117-122PubMedCrossRefGoogle Scholar
  2. 2.
    Bonadonna G, Brusamolino E, Valagussa P, et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405 - 410PubMedCrossRefGoogle Scholar
  3. 3.
    Mouridsen HT, Palshof T (1983) Adjuvant systemic therapy in breast cancer; a review. Eur J Cancer Clin Oncol 19: 1753 - 1770PubMedCrossRefGoogle Scholar
  4. 4.
    Wrange Ö, Nordenskjöld B, Gustafsson J-A (1978) Cytosol estradiol receptor in human mammary carcinoma: An assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85: 461-475Google Scholar
  5. 5.
    Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10 - 15PubMedCrossRefGoogle Scholar
  6. 6.
    Peto R, Pike MC, Armitage P, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39PubMedCrossRefGoogle Scholar
  7. 7.
    Cox DR (1972) Regression models and life tables. JR Stat Soc [B] 34: 187 - 220Google Scholar
  8. 8.
    Knight WA, Rivkin SE, Glucksberg H, et al. (1983) Adjuvant therapy of breast cancer: the Southwest Oncology Group experience. Breast Cancer Res Treat [Suppl 1] 3: 27 - 33CrossRefGoogle Scholar
  9. 9.
    Strender L-E, Wallgren A, Arndt J, et al. (1981) Adjuvant radiotherapy in operable breast cancer: correlation between dose in internal mammary nodes and prognosis. Int J Radiat Oncol Biol Phys 7: 1319 - 1325PubMedCrossRefGoogle Scholar
  10. 10.
    Nolvadex Adjuvant Trial Organisation (1983) Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet 1: 257 - 261Google Scholar
  11. 11.
    Wallgren A, Baral E, Glas U, et al. (1981) Adjuvant treatment of breast cancer with tamoxifen and combination chemotherapy in postmenopausal women. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 345 - 350Google Scholar
  12. 12.
    Palshof T, Mouridsen HT, Daehnfeldt JL (1980) Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. Eur J Cancer 16: 183-187Google Scholar
  13. 13.
    Pearson OH, Hubay CA, Marshall JS, et al. (1983) Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results. Breast Cancer Res Treat [Suppl 1] 3: 61 - 68CrossRefGoogle Scholar
  14. 14.
    Fisher B (1983) Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report. Breast Cancer Res Treat [Suppl 1] 3: 7 - 17CrossRefGoogle Scholar
  15. 15.
    Baum M, Brinkley DM, Dossett JA, et al. (1983) Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1: 450CrossRefGoogle Scholar
  16. 16.
    Baum M (1982) Scientific empirism and clinical medicine. In: Baum M, Kay R, Scheurlen H (eds) Clinical trials in early breast cancer. Birkhäuser, Basel, pp 35 - 46Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • A. Wallgren
    • 1
  • E. Baral
    • 1
  • U. Beling
    • 1
  • J. Carstensen
    • 1
  • S. Friberg
    • 1
  • U. Glas
    • 1
  • M. Kaigas
    • 1
  • L. Skoog
    • 1
  1. 1.Stockholm-Gotland Oncologie Centre, RadiumhemmetKarolinska HospitalStockholmSweden

Personalised recommendations